Elhami Hannan, MD
Nephrology · Richland, WANPI 1093803884
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Travere Therapeutics, Inc. accounts for 71.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $5,922 and has fallen 91.2% since, to $522 in 2025. Among nephrology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $141.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$6K
- Akebia Therapeutics Inc$827
- Boehringer Ingelheim$268
- Bayer$232
- AstraZeneca$196
- Vifor Pharma, Inc.$156
- plus $722 from 10 others
What the payments were for
- Consulting fees$2,70032%
- Travel & lodging$1,68320%
- Food & beverage$4,10348%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 26 | $6,111 |
| Akebia Therapeutics Inc | 8 | $827 |
| Boehringer Ingelheim | 3 | $268 |
| Bayer | 2 | $232 |
| AstraZeneca(2 entities) | 2 | $196 |
| Vifor Pharma, Inc. | 4 | $156 |
| Otsuka America Pharmaceutical, Inc. | 3 | $150 |
| Baxter Healthcare | 2 | $140 |
| Novo Nordisk | 2 | $138 |
| Ardelyx, Inc. | 1 | $126 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $46 |
| Innovation Technologies Inc | 1 | $34 |
| Novartis | 2 | $33 |
| Veloxis Pharmaceuticals, Inc. | 1 | $22 |
| GSK | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,512 in reported general payments places this provider in the 90th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeltassaPatiromer Calcium Sorbitex | 28 | $51,940 |
| Sevelamer Carbonate | 69 | $18,789 |
| FarxigaDapagliflozin Propanediol | 14 | $8,184 |
| ProsolParenteral Amino Acid 20% No.1 | 13 | $2,899 |
| Losartan Potassium | 256 | $2,434 |
| Calcium Acetate | 32 | $2,209 |
| Torsemide | 101 | $1,528 |
| Midodrine Hcl | 27 | $1,473 |
| Chlorthalidone | 63 | $1,448 |
| Metolazone | 15 | $703 |
| Calcitriol | 41 | $698 |
| Spironolactone | 64 | $661 |
| Potassium Chloride | 24 | $661 |
| Lisinopril | 96 | $657 |
| Nifedipine ErNifedipine | 13 | $640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $196 | $8,18414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 237 nephrology providers in Washington.
Other nephrology in Richland
- Fadi AkoumRichland$973
- Kathrine TuttleSpokane$421K
- Osama AmroSeattle$395K
- Dmitri VasinBremerton$215K
- Ian de BoerSeattle$117K
- Nicolae LecaSeattle$101K
- Syeda AhmadSeattle$68K
- Charles MinnTacoma$67K
- Saw Hnin MuShoreline$25K
- Mahesh DangalVancouver$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.